Overview
Jinliang Qi practices practicing medicine in Nanjing, China.
Their clinical expertise encompasses Methicillin-Resistant Staphylococcus Aureus (MRSA), H1N1 Influenza, Triple-Negative Breast Cancer, and Colorectal Cancer.
They are actively involved in clinical research, co-authoring 36 peer reviewed articles.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Jinliang Qi
Is Jinliang Qi a top-rated expert for Methicillin-Resistant Staphylococcus Aureus (MRSA)?
MediFind is an objective health platform that identifies experts based on real-world data. Jinliang Qi is classified as an Experienced expert for Methicillin-Resistant Staphylococcus Aureus (MRSA), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Jinliang Qi participate in research or clinical trials?
Yes. Jinliang Qi has published 36 articles and abstracts on conditions like Methicillin-Resistant Staphylococcus Aureus (MRSA). You can view a list of Jinliang Qi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Colorectal CancerQi isExperienced. Learn about Colorectal Cancer.
- H1N1 InfluenzaQi isExperienced. Learn about H1N1 Influenza.
- Methicillin-Resistant Staphylococcus Aureus (MRSA)
- Triple-Negative Breast Cancer